The Company recently announced that it would advance development of TZLS-501, a dual-action IL-6R monoclonal antibody targeting both membrane-bound and soluble forms of IL-6R. This decision was based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback